Coya Therapeutics, Inc.
COYA Nasdaq Pharmaceutical Preparations Financials FY2021โFY2025
Last close ยท Oct 23, 2026
$3.94
4.8%
Revenue
Total sales reported in the income statement.
$7.9M
123.6%
vs prior year
Operating margin
Operating income as a share of revenue.
โ283.9%
201.5ย pts
Net income
Profit after all expenses, interest and tax.
โ$21.2M
Free cash flow
Cash from operations minus capital spending.
โ
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ
Market cap
Last close times the latest diluted share count, so it is approximate.
$92.4M
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
โ
On โ$1.07 EPS (TTM)
What Coya Therapeutics, Inc. does
No business description yet.
- Legal name
- Coya Therapeutics, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K ยท Mar 16, 2026
- Accession ยท CIK
- 0001193125-26-107281
0001835022
Revenue and margins
Coya Therapeutics, Inc. had $7.9M of revenue in fiscal 2025, up 123.6% on the year before.
FY21
Revenue โ
FY22
Revenue $0.0M
FY23
Revenue $6.0M
FY24
Revenue $3.6M
FY25
Revenue $7.9M
Q3 '23
Revenue $0.0M
Q4 '23
Revenue $6.0M
Q1 '24
Revenue $0.1M
Q2 '24
Revenue $3.4M
Q3 '24
Revenue $0.0M
Q4 '24
Revenue $0.0M
Q1 '25
Revenue $0.3M
Q2 '25
Revenue $0.2M
Q3 '25
Revenue $3.6M
Q4 '25
Revenue $4.0M
Q1 '26
Revenue $0.3M
Q2 '26
Revenue $0.2M
FY21
Gross โ
Operating โ
Net โ
FCF โ
FY22
Gross โ
Operating โ
Net โ
FCF โ
FY23
Gross โ
Operating โ131.7%
Net โ133.1%
FCF โ
FY24
Gross โ
Operating โ485.3%
Net โ418.7%
FCF โ
FY25
Gross โ
Operating โ283.9%
Net โ267.1%
FCF โ
Gross
Operating
Net
FCF
Q3 '23
Gross โ
Operating โ
Net โ
FCF โ
Q4 '23
Gross โ
Operating 30.2%
Net 21.1%
FCF โ
Q1 '24
Gross โ
Operating โ4,324.1%
Net โ3,984.1%
FCF โ
Q2 '24
Gross โ
Operating โ94.5%
Net โ84.4%
FCF โ
Q3 '24
Gross โ
Operating โ
Net โ
FCF โ
Q4 '24
Gross โ
Operating โ204,015.0%
Net โ145,790.0%
FCF โ
Q1 '25
Gross โ
Operating โ2,976.7%
Net โ2,833.2%
FCF โ
Q2 '25
Gross โ
Operating โ3,920.8%
Net โ3,725.6%
FCF โ
Q3 '25
Gross โ
Operating โ68.3%
Net โ59.4%
FCF โ
Q4 '25
Gross โ
Operating โ152.3%
Net โ144.2%
FCF โ
Q1 '26
Gross โ
Operating โ3,042.7%
Net โ2,870.2%
FCF โ
Q2 '26
Gross โ
Operating โ2,891.7%
Net โ2,724.0%
FCF โ
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY21
Net income โ$4.9M
FY22
Net income โ$12.2M
FY23
Net income โ$8.0M
FY24
Net income โ$14.9M
FY25
Net income โ$21.2M
Q3 '23
Net income โ$3.4M
Q4 '23
Net income $1.3M
Q1 '24
Net income โ$5.1M
Q2 '24
Net income โ$2.9M
Q3 '24
Net income โ$4.0M
Q4 '24
Net income โ$2.9M
Q1 '25
Net income โ$7.3M
Q2 '25
Net income โ$6.1M
Q3 '25
Net income โ$2.1M
Q4 '25
Net income โ$5.7M
Q1 '26
Net income โ$7.2M
Q2 '26
Net income โ$6.6M
FY21
Diluted EPS โ$1.89
FY22
Diluted EPS โ$4.73
FY23
Diluted EPS โ$0.79
FY24
Diluted EPS โ$0.98
FY25
Diluted EPS โ$1.27
Q3 '23
Diluted EPS โ$0.34
Q4 '23
Diluted EPS $0.14
Q1 '24
Diluted EPS โ$0.35
Q2 '24
Diluted EPS โ$0.19
Q3 '24
Diluted EPS โ$0.26
Q4 '24
Diluted EPS โ$0.18
Q1 '25
Diluted EPS โ$0.44
Q2 '25
Diluted EPS โ$0.36
Q3 '25
Diluted EPS โ$0.13
Q4 '25
Diluted EPS โ$0.34
Q1 '26
Diluted EPS โ$0.32
Q2 '26
Diluted EPS โ$0.28
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY21
Return on capital โ
Return on equity โ134.3%
Return on assets โ102.1%
FY22
Return on capital โ
Return on equity โ
Return on assets โ185.7%
FY23
Return on capital โ
Return on equity โ58.6%
Return on assets โ32.2%
FY24
Return on capital โ
Return on equity โ39.6%
Return on assets โ34.8%
FY25
Return on capital โ
Return on equity โ51.4%
Return on assets โ45.0%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was โ in fiscal 2025, โ of revenue. Cash from operations minus capital spending.
FY21
Free cash flow โ
FY22
Free cash flow โ
FY23
Free cash flow โ
FY24
Free cash flow โ
FY25
Free cash flow โ
FY21
Cash from operations โ$3.9M
Capital spending โ
FY22
Cash from operations โ$7.2M
Capital spending โ
FY23
Cash from operations โ$11.2M
Capital spending โ
FY24
Cash from operations โ$10.3M
Capital spending โ
FY25
Cash from operations โ$10.7M
Capital spending โ
Cash from operations
Capital spending
Q3 '23
Cash from operations โ$2.2M
Capital spending โ
Q4 '23
Cash from operations โ$2.2M
Capital spending โ
Q1 '24
Cash from operations $2.1M
Capital spending โ
Q2 '24
Cash from operations โ$4.6M
Capital spending โ
Q3 '24
Cash from operations โ$5.5M
Capital spending โ
Q4 '24
Cash from operations โ$2.4M
Capital spending โ
Q1 '25
Cash from operations โ$2.8M
Capital spending โ
Q2 '25
Cash from operations โ$5.8M
Capital spending โ
Q3 '25
Cash from operations โ$1.1M
Capital spending โ
Q4 '25
Cash from operations โ$1.0M
Capital spending โ
Q1 '26
Cash from operations โ$6.2M
Capital spending โ
Q2 '26
Cash from operations โ$7.4M
Capital spending โ
Cash from operations
Capital spending
Dividends, buybacks and share count
Coya Therapeutics, Inc. returned โ to shareholders in fiscal 2025. The diluted share count rose 9.8%.
FY21
Dividends โ
Buybacks โ
FY22
Dividends โ
Buybacks โ
FY23
Dividends โ
Buybacks โ
FY24
Dividends โ
Buybacks โ
FY25
Dividends โ
Buybacks โ
Dividends
Buybacks
FY21
Diluted shares 0.00B
FY22
Diluted shares 0.00B
FY23
Diluted shares 0.01B
FY24
Diluted shares 0.02B
FY25
Diluted shares 0.02B
Balance sheet
Cash, debt and the ratios that show how comfortably Coya Therapeutics, Inc. can carry it.
FY21
Cash $4.3M
Debt โ
FY22
Cash $5.9M
Debt โ
FY23
Cash $32.6M
Debt โ
FY24
Cash $38.3M
Debt โ
FY25
Cash $46.8M
Debt โ
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $4.3M | $5.9M | $32.6M | $38.3M | $46.8M |
| Current ratio | 4.0x | 1.9x | 8.2x | 11.6x | 8.5x |
| Quick ratio | 4.0x | 1.9x | 8.2x | 11.6x | 8.5x |
| Total assets | $4.8M | $8.4M | $41.3M | $44.3M | $50.0M |
| Total liabilities | $1.1M | $16.8M | $5.6M | $4.8M | $6.9M |
| Shareholders' equity | $3.6M | โ$8.4M | $35.6M | $39.6M | $43.0M |
| Net debt (โ = net cash) | โ | โ | โ | โ | โ |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ | โ |
| F-score | โ / 3 | โ / 6 | 3 / 7 | 2 / 7 | 2 / 7 |
| Accruals ratio | โ20.6% | โ75.9% | 12.9% | โ10.7% | โ22.2% |
| Altman Z'' | โ2.62 | โ12.69 | 9.07 | 9.09 | 5.24 |
5 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | โ | $0.0M | $6.0M | $3.6M | $7.9M |
| Research and development | $2.5M | $4.4M | $5.5M | $11.9M | $16.7M |
| Operating income | โ$4.9M | โ$9.8M | โ$7.9M | โ$17.2M | โ$22.6M |
| Pretax income | โ | โ$12.2M | โ$7.3M | โ$15.6M | โ$21.2M |
| Income tax | โ | $0.0M | $0.7M | โ$0.7M | $0.0M |
| Net income | โ$4.9M | โ$12.2M | โ$8.0M | โ$14.9M | โ$21.2M |
| Diluted EPS | โ$1.89 | โ$4.73 | โ$0.79 | โ$0.98 | โ$1.27 |
| Diluted shares | 0.00B | 0.00B | 0.01B | 0.02B | 0.02B |
| Cash flow | |||||
| Cash from operations | โ$3.9M | โ$7.2M | โ$11.2M | โ$10.3M | โ$10.7M |
| Depreciation and amortization | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Stock-based compensation | $0.2M | $0.2M | $0.9M | $2.7M | $4.3M |
| Balance sheet | |||||
| Cash and short-term investments | $4.3M | $5.9M | $32.6M | $38.3M | $46.8M |
| Current assets | $4.6M | $7.2M | $41.2M | $44.3M | $49.9M |
| Current liabilities | $1.1M | $3.8M | $5.1M | $3.8M | $5.9M |
| Property and equipment, net | $0.1M | $0.1M | $0.1M | $0.0M | $0.0M |
| Total assets | $4.8M | $8.4M | $41.3M | $44.3M | $50.0M |
| Total liabilities | $1.1M | $16.8M | $5.6M | $4.8M | $6.9M |
| Preferred stock | $8.8M | $8.8M | โ | โ | โ |
| Shareholders' equity | $3.6M | โ$8.4M | $35.6M | $39.6M | $43.0M |
| Margins | |||||
| Operating margin | โ | โ | โ131.7% | โ485.3% | โ283.9% |
| EBITDA margin | โ | โ | โ131.2% | โ484.6% | โ283.5% |
| Net margin | โ | โ | โ133.1% | โ418.7% | โ267.1% |
| Returns | |||||
| Return on capital employed | โ133.7% | โ214.6% | โ21.8% | โ42.6% | โ51.2% |
| Return on equity | โ134.3% | โ | โ58.6% | โ39.6% | โ51.4% |
| Return on assets | โ102.1% | โ185.7% | โ32.2% | โ34.8% | โ45.0% |
| Return on tangible equity | โ134.3% | โ | โ22.4% | โ37.6% | โ49.3% |
| Growth | |||||
| Revenue growth | โ | โ | โ | โ40.8% | 123.6% |
| Share count change | โ | 0.0% | 292.4% | 49.9% | 9.8% |
| Financial health | |||||
| Current ratio | 4.0x | 1.9x | 8.2x | 11.6x | 8.5x |
| Quick ratio | 4.0x | 1.9x | 8.2x | 11.6x | 8.5x |
| Capital allocation | |||||
| Stock comp / revenue | โ | โ | 14.5% | 74.9% | 54.0% |
| Quality scores | |||||
| Piotroski F-score | โ | โ | 3.0 | 2.0 | 2.0 |
| Altman Z'' | โ2.6 | โ12.7 | 9.1 | 9.1 | 5.2 |
| Accruals ratio | โ20.6% | โ75.9% | 12.9% | โ10.7% | โ22.2% |
Source: SEC EDGAR XBRL filings (CIK 0001835022). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ not investment advice. Check the original filings before relying on any figure.